Jingchen Wei

Jingchen Wei

Auto-generated profile, based on publicly available information

Jingchen Wei

College of Pharmacy, Guilin Medical University, Guilin, China

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2021 in Analytical Cellular Pathology
Verified
Journal Article
Open access
PDF file
YLYunfei Lu
Yunfei Lu
JLJing Lin
Jing Lin
MDMeng Duan
Meng Duan
YRYing Rui
Ying Rui
HZHao Zheng
Hao Zheng
JWJingchen Wei
Jingchen Wei
Oral squamous cell carcinoma (OSCC) is a malignant tumour originating from the mucosal lining of the oral cavity. Its characteristics include hidden onset, high recurrence, and distant metastasis after operation. At present, clinical treatment usually includes surgery, chemotherapy, radiotherapy, or the joint use of these modalities. Unfortunately, multidrug resistant is one of the important obstacles that causes cancer chemotherapy failure. Anlotinib, which has recently been proven to have good antitumour effects, is a novel multitargeted tyrosine kinase inhibitor. However, there are few studies of the anlotinib-associated mechanism in OSCC and its underlying molecular mechanism. In our study, in vitro models of human oral squamous cell carcinoma HSC-3 cells were used to determine the efficacy of anlotinib. On the one hand, we showed that anlotinib treatment significantly reduced the viability and proliferation of HSC-3 cells and decreased cell migration by inhibiting the activation of the Akt phosphorylation pathway. On the other side, anlotinib inhibited PI3K/Akt/Bad phosphorylation and promoted apoptosis of HSC-3 cells by activating RAS protein expression. In brief, these results indicated that anlotinib had prominent antitumour activity in OSCC, mainly by inhibiting the PI3K/Akt phosphorylation pathway. This work provides evidences and a basic principle for using anlotinib to treat patients with OSCC for clinical research.

16 February 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
JWJingchen Wei
Jingchen Wei
YLYunfei Lu
Yunfei Lu
YRYing Rui
Ying Rui
XZXuanyu Zhu
Xuanyu Zhu
SHSongqing He
Songqing He
QXQing Xu
Qing Xu
COVID-19 pneumonia has now spread widely in the world. Currently, no specific antiviral drugs are available. The vaccine is the most effective way to control the epidemic. Passive immune antibodies are also an effective method to prevent and cure COVID-19 pneumonia. We used the SARS-CoV-2 S receptor-binding domain (RBD) as an antigen to immunize layers in order to extract, separate, and purify SARS-CoV-2-IgY from egg yolk. SARS-CoV-2-IgY (S-IgY)can block the entry of SARS-CoV-2 into the Cells and reduce the viral load in cells. The Half effective concentration (EC 50 ) of W3-IgY (S-IgY in the third week after immunization) is 1.35 ± 0.15nM. The EC 50 of W9-IgY (S-IgY in the ninth week after immunization) is 2.76 ± 1.54 nM. When the dose of S-IgY is 55 nM, the fluorescence representing intracellular viral protein is obviously weakened in Immunofluorescence microscopy. Results of Sars-CoV-2 /Vero E6 cell experiment confirmed that S-IgY has a strong antiviral effect on SARS-CoV-2, and its (EC 50 ) is 27.78 ±1.54 nM vs 3,259 ± 159.62 nM of Redesivir (differ > 106 times P<0 . 001 ). S-IgY can inhibit the entry and replication of SARS-CoV-2, which is related to its targeting the ACE2 binding domain. S-IgY is safe, efficient, stable, and easy to obtain. This antibody can be an effective tool for preventing and treating COVID-19 pneumonia. Abstract Figure: Fig. 1. Graphical The figure briefly illustrates that the preparation and extraction of S-IgY and its anti-S-CoV-2 mechanism is to inhibit the entry and replication of SARS-CoV-2 by targeting the ACE2.

15 February 2025 in Rapid Communications in Mass Spectrometry
Verified
Journal Article
Closed access
GYGuixiang Yang
Guixiang Yang
YCYalan Cui
Yalan Cui
XZXingxing Zong
Xingxing Zong
QJQian Jin
Qian Jin
YZYi Zhang
Yi Zhang
JWJingchen Wei
Jingchen Wei

6 June 2025 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
GYGuixiang Yang
Guixiang Yang
YZYi Zhang
Yi Zhang
CLChong Li
Chong Li
XXXingle Xia
Xingle Xia
QJQian Jin
Qian Jin
CWChen Wang
Chen Wang

26 February 2026 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
CLChong Li
Chong Li
YZYi Zhang
Yi Zhang
GYGuixiang Yang
Guixiang Yang
QJQian Jin
Qian Jin
WCWang Chen
Wang Chen
LLLiqin Li
Liqin Li

1 April 2026 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
YRYing Rui
Ying Rui
YWYan Wang
Yan Wang
HGHongfei Gong
Hongfei Gong
XZXuanyu Zhu
Xuanyu Zhu
QXQing Xu
Qing Xu
JWJingchen Wei
Jingchen Wei
Background: Oral squamous cell carcinoma (OSCC) remains a substantial global health burden. According to the latest global cancer statistics, it accounts for an estimated 300,000 new cases and 100,000 deaths annually. This study aimed to investigate the pharmacological effects of digitoxin, a cardenolide glycoside, on the modulation of proliferative capacity and apoptotic induction in human OSCC human tongue squamous carcinoma (HSC-3) cells. Methods: In vitro, HSC-3 cells were treated with graded concentrations of digitoxin. Cell viability and colony formation were measured by Cell Counting Kit-8 (CCK-8) and clonogenic assays, respectively. Apoptosis and cell cycle progression were analysed by flow cytometry, and mitochondrial membrane potential (ΔΨm) and reactive oxygen species (ROS) levels were visualised by fluorescence microscopy. Expression of cell cycle and apoptosis-related proteins was examined by Western blotting. The involvement of oxidative stress was assessed using N-acetylcysteine (NAC) mediated ROS blockade. In vivo, HSC-3 xenograft-bearing nude mice were administered digitoxin, and tumour growth was monitored; tumour tissues were subsequently analysed for Ki67 and cleaved-cysteinyl aspartate specific proteinase 3 (cleaved Caspase-3) expression. Results: Digitoxin treatment reduced the viability of HSC-3 cells in a concentration-dependent manner and concurrently increased the apoptotic fraction. Mechanistically, digitoxin induced G2/M phase arrest, which was associated with suppression of the cell division cycle 25 homolog C (Cdc25C) phosphatase and decreased abundance of the cyclin B1-CDK1 complex, together enforcing sustained cyclin-dependent kinase 1 (CDK1) inactivation. In parallel, digitoxin triggered mitochondrial dysfunction, as evidenced by loss of ΔΨm and a marked increase in intracellular ROS accumulation. These events were accompanied by upregulation of B-cell lymphoma-2 (Bcl-2) associated x protein (Bax), downregulation of Bcl-2, and elevated levels of cytosolic cytochrome c (Cyt c) and cleaved-cysteinyl aspartate specific proteinase 9 (cleaved Caspase-9), indicating engagement of the intrinsic apoptotic pathway. Pharmacological blockade of ROS with NAC abrogated digitoxin reversed the modulation of Bcl-2 family proteins, and restored cell viability, confirming that oxidative stress functions as an essential upstream signal coordinating both cytostatic and cytotoxic arms of digitoxin’s activity. In vivo, digitoxin significantly suppressed the growth of HSC-3 xenograft tumours. Together, these results establish that digitoxin exerts anti-tumour effects in OSCC through ROS-mediated mitochondrial apoptosis and cell cycle checkpoint engagement. Conclusions: Digitoxin inhibited the growth of HSC-3 cells both in vitro and in vivo.